{Reference Type}: Journal Article
{Title}: Inhaled protein/peptide-based therapies for respiratory disease.
{Author}: Fellner RC;Terryah ST;Tarran R;
{Journal}: Mol Cell Pediatr
{Volume}: 3
{Issue}: 1
{Year}: Dec 2016
暂无{DOI}: 10.1186/s40348-016-0044-8
{Abstract}: Asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis (CF) are all chronic pulmonary diseases, albeit with different etiologies, that are characterized by airflow limitation, chronic inflammation, and abnormal mucus production/rheology. Small synthetic molecule-based therapies are commonly prescribed for all three diseases. However, there has been increased interest in "biologicals" to treat these diseases. Biologicals typically constitute protein- or peptide-based therapies and are often more potent than small molecule-based drugs. In this review, we shall describe the pros and cons of several different biological-based therapies for respiratory disease, including dornase alfa, a recombinant DNAase that reduces mucus viscosity and short palate lung and nasal epithelial clone 1 (SPLUNC1)-derived peptides that treat Na(+) hyperabsorption and rebalance CF airway surface liquid homeostasis.